Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2017 3
2018 4
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.
The challenges of describing rehabilitation services: A discussion paper.
Røe C, Kirkevold M, Andelic N, Soberg HL, Sveen U, Bautz-Holter E, Jahnsen R, van Walsem MR, Kildal Bragstad L, Gabrielsen Hjelle E, Klevberg G, Oretorp P, Habberstad A, Hagfors J, Væhle R, Engen G, Gutenbrunner C. Røe C, et al. Among authors: hagfors j. J Rehabil Med. 2018 Feb 13;50(2):151-158. doi: 10.2340/16501977-2299. J Rehabil Med. 2018. PMID: 29260837 Free article.
Structured Goal Planning and Supportive Telephone Follow-up in Rheumatology Care: Results From a Pragmatic, Stepped-Wedge, Cluster-Randomized Trial.
Berdal G, Bø I, Dager TN, Dingsør A, Eppeland SG, Hagfors J, Hamnes B, Mowinckel P, Nielsen M, Sand-Svartrud AL, Slungaard B, Wigers SH, Hagen KB, Dagfinrud HS, Kjeken I. Berdal G, et al. Among authors: hagfors j. Arthritis Care Res (Hoboken). 2018 Nov;70(11):1576-1586. doi: 10.1002/acr.23520. Arthritis Care Res (Hoboken). 2018. PMID: 29361197 Clinical Trial.
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
Goll GL, Jørgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak Ø, Baigh S, Blomgren IM, Brenna Ø, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G, Henriksen M, Hoie SS, Krogh J, Midtgard IP, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid HU, Strand EK, Skjetne K, Seeberg KA, Torp R, Ystrøm CM, Vold C, Zettel CC, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J, Kvien TK. Goll GL, et al. Among authors: hagfors j. J Intern Med. 2019 Jun;285(6):653-669. doi: 10.1111/joim.12880. Epub 2019 Apr 12. J Intern Med. 2019. PMID: 30762274 Free PMC article. Clinical Trial.
Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries.
Glintborg B, Lindström U, Aaltonen K, Kristianslund EK, Gudbjornsson B, Chatzidionysiou K, Askling J, Nordström D, Hetland ML, Di Giuseppe D, Dreyer L, Kristensen LE, Jørgensen TS, Eklund K, Grondal G, Ernestam S, Joensuu J, Törmänen M, Skydsgaard H, Hagfors J, Kvien TK, Lie E, Fagerli K, Geirsson AJ, Jonsson H, Provan SA, Krogh NS, Jacobsson L. Glintborg B, et al. Among authors: hagfors j. Scand J Rheumatol. 2018 Nov;47(6):465-474. doi: 10.1080/03009742.2018.1444199. Epub 2018 Aug 2. Scand J Rheumatol. 2018. PMID: 30070923
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials.
Jørgensen KK, Goll GL, Sexton J, Bolstad N, Olsen IC, Asak Ø, Berset IP, Blomgren IM, Dvergsnes K, Florholmen J, Frigstad SO, Henriksen M, Hagfors J, Huppertz-Hauss G, Haavardsholm EA, Klaasen RA, Moum B, Noraberg G, Prestegård U, Rydning JH, Sagatun L, Seeberg KA, Torp R, Vold C, Warren DJ, Ystrøm CM, Lundin KEA, Kvien T, Jahnsen J. Jørgensen KK, et al. Among authors: hagfors j. BioDrugs. 2020 Oct;34(5):681-694. doi: 10.1007/s40259-020-00438-7. BioDrugs. 2020. PMID: 32965617 Free PMC article. Clinical Trial.
Evaluation of a structured goal planning and tailored follow-up programme in rehabilitation for patients with rheumatic diseases: protocol for a pragmatic, stepped-wedge cluster randomized trial.
Kjeken I, Berdal G, Bø I, Dager T, Dingsør A, Hagfors J, Hamnes B, Eppeland SG, Fjerstad E, Mowinckel P, Nielsen M, Rørstad RW, Sand-Svartrud AL, Slungaard B, Wigers SH, Hagen KB. Kjeken I, et al. Among authors: hagfors j. BMC Musculoskelet Disord. 2014 May 14;15:153. doi: 10.1186/1471-2474-15-153. BMC Musculoskelet Disord. 2014. PMID: 24886382 Free PMC article. Clinical Trial.
Rehabilitation for patients with rheumatic diseases: Patient experiences of a structured goal planning and tailored follow-up programme.
Dager TN, Kjeken I, Berdal G, Sand-Svartrud AL, Bø I, Dingsør A, Eppeland SG, Hagfors J, Hamnes B, Nielsen M, Slungaard B, Wigers SH, Hauge MI. Dager TN, et al. Among authors: hagfors j. SAGE Open Med. 2017 Nov 10;5:2050312117739786. doi: 10.1177/2050312117739786. eCollection 2017. SAGE Open Med. 2017. PMID: 29163943 Free PMC article.